A carregar...

Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.

The aromatase inhibitor, 'pyridoglutethimide' (PyG), has been shown previously to suppress serum oestrogen levels in postmenopausal breast cancer patients and to achieve clinical responses at a dose of 500 mg twice daily (b.d.). This report gives the results of a detailed pharmacokinetic a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dowsett, M., MacNeill, F., Mehta, A., Newton, C., Haynes, B., Jones, A., Jarman, M., Lonning, P., Powles, T. J., Coombes, R. C.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 1991
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1977449/
https://ncbi.nlm.nih.gov/pubmed/1931611
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!